perampanel

Common name: perampanel

Trade name: Fycompa

Full names: perampanel, Vectin, Fycompa, perampanel

Indications:

Additional treatment of partial-onset epilepsy (with or without secondary generalized seizures) in adults and children 12 years and older.

Usage and dosage:

Take once a day, before going to bed, on an empty stomach or with food.

This product should be swallowed whole and should not be chewed, crushed or broken. Since there are no marks on the medicine, this product cannot be opened evenly.

Adverse reactions:

Dizziness, drowsiness, headache, fatigue, irritability, nausea, falls

Contraindications:

Contraindicated for those allergic to the active ingredients of this product or lactose.

Because this product contains lactose, patients with rare hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose intractable disease should not use this product.

Notes:

1. Suicidal ideation

2. Various neurological diseases

3. Oral contraceptives

4. Falls

5. Attacks

6. Other symptoms of mental illness

7. Social environment< /p>

8. Potential for abuse

Storage:

Keep airtight at no more than 30°C

Mechanism of action:

The active substance perampanel in Fycompa is an anti-epileptic drug. Epilepsy is caused by excessive electrical activity in the brain. While the exact mechanism by which Fycompa works is not fully understood, it is thought to block the effects of the neurotransmitter glutamate. Neurotransmitters are naturally occurring chemicals in the nervous system that allow nerve cells to communicate with each other. Glutamate is the primary stimulatory neurotransmitter in nerve cells that can initiate and sustain epileptic seizures. Therefore, by blocking the effects of glutamate, Fycompa is thought to stop epileptic seizures.

Safety and Efficacy:

The efficacy of perampanel, a partial-onset seizure treatment drug, was established in three 19-week randomized, double-blind, placebo-controlled, multicenter add-on treatment trials in adult and adolescent patients. Subjects had partial seizures with or without secondary generalized seizures that were not adequately controlled while receiving 1 to 3 concomitant AEDs. During the 6-week baseline period, subjects had more than 5 seizures and no more than 25 days of epilepsy-free seizures. Across the three trials, subjects' average epilepsy duration was approximately 2106 years. 85.3% and 89.1% of patients used 2-3 combined AEDs with or without vagus nerve stimulation.